About
Acepodia is a privately held biotechnology company committed to developing innovative, highly effective cell therapies that are broadly accessible for patients with cancer. Acepodia’s proprietary ACC (Antibody-Cell Conjugation) technology platform links tumor targeting antibodies to the surface of a novel and proprietary human NK cell line that have been specifically selected for their potent antitumor activity. The ACC technology can be seamlessly combined with currently available antibodies allowing for the rapid development of new targeted therapies in multiple indications, without the need for genetic engineering.